579474-47-8

Basic information

• Product Name: (2-AMINO-4-FLUORO-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (2-AMINO-4-FLUORO-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER;Carbamic acid, N-(2-amino-4-fluorophenyl)-, 1,1-dimethylethyl ester;N1-(tert-Butoxycarbonyl)-4-fluoro-1,2-phenylenediamine;N1-(tert-Butoxycarbonyl)-4-fluoro-1,2-phenylenediamine
• CAS NO: 579474-47-8
• Molecular Formula: C₁₁H₁₅FN₂O₂
• Molecular Weight: 226.25
• Mol File: 579474-47-8.mol
• Article Data: 17

Chemical Properties

• Melting Point: 135.0 to 139.0 °C
• Boiling Point: 281.0±30.0 °C(Predicted)
• Appearance: /
• Density: 1.223±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 12.45±0.70(Predicted)
• CAS DataBase Reference: (2-AMINO-4-FLUORO-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (2-AMINO-4-FLUORO-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(579474-47-8)
• EPA Substance Registry System: (2-AMINO-4-FLUORO-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(579474-47-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 579474-47-8(Hazardous Substances Data)

Usage

General Description

(2-Amino-4-fluoro-phenyl)-carbamic acid tert-butyl ester is a chemical compound with the molecular formula C11H15FN2O2. It is a tert-butyl ester of (2-amino-4-fluoro-phenyl)-carbamic acid and is used in the synthesis of various pharmaceutical compounds. This chemical may be used as an intermediate in the production of certain drugs and compounds due to its unique structure and properties. It is important to handle this chemical with care and follow proper safety precautions when handling and using it in the laboratory.

Upstream product

• 579474-17-2 (4-fluoro-2-nitrophenyl)carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 367-31-7 4-fluoro-1,2-phenylenediamine 
• 364-78-3 2-nitro-4-fluoroaniline 

Downstream Products

• 579476-82-7 {4-fluoro-2-[3-oxo-3-(3-pyridin-3-yl-phenyl)-propionylamino]-phenyl}-carbamic acid tert-butyl ester 
• 579476-84-9 {4-fluoro-2-[3-oxo-3-(3-pyridin-4-yl-phenyl)-propionylamino]-phenyl}-carbamic acid tert-butyl ester 
• 579476-87-2 (4-fluoro-2-{3-[3-(6-methyl-pyridin-3-yl)-phenyl]-3-oxo-propionylamino}-phenyl)-carbamic acid tert-butyl ester 
• 579476-95-2 (4-fluoro-2-{3-[3-(2-methyl-pyridin-3-yl)-phenyl]-3-oxo-propionylamino}-phenyl)-carbamic acid tert-butyl ester 
• 579477-70-6 (4-fluoro-2-{3-[3-(2-methyl-pyridin-4-yl)-phenyl]-3-oxo-propionylamino}-phenyl)-carbamic acid tert-butyl ester 
• 1233700-41-8 tert-butyl 2-(4-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-2-oxoethyl)phenoxy)butanamido)-4-fluorophenylcarbamate 

Relevant articles and documents

Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors

Currently, synergistic inhibition of poly(ADP-ribose) polymerase-1 (PARP-1) and histone deacetylases (HDACs) has been a potential effective strategy for cancer treatment. Herein, by combining critical pharmacophores in approved drugs olaparib and chidamid

Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase 1 (HDAC1) dual inhibitors derived from the natural product saprorthoquinone

The discovery of IDO1 and HDAC1 dual inhibitors may provide a novel strategy for cancer treatment by taking advantages of both immunotherapeutic and epigenetic drugs. In this paper, saprorthoquinone (1) and 13 of its analogues from Salvia prionitis Hance were investigated for their SAR against IDO1, the results demonstrated the ortho-quinone was a key pharmacophore. Then a series of IDO1 and HDAC dual inhibitors connected by appropriate linkers were designed, synthesized, and evaluated from the hit compound saprorthoquinone (1). Among them, compound 33d showed balanced activity against both IDO1 (IC50 = 0.73 μM) and HDAC1 (IC50 = 0.46 μM). Importantly, the structure of 33d suggested that an ortho-quinone pharmacophore and a N-(2- aminophenyl) amide pharmacophore were necessary for the IDO inhibition and HDAC inhibition respectively. Meanwhile, these two pharmacophore groups should be combined by a pentane linker. Moreover, the binding modes of 33d to the enzyme active site showed that the hydrogen bond with Leu234 of IDO1 appeared to confer increased potency to this class of inhibitors, which may explain the higher activity of 33d. This study provides a new strategy for future IDO1/HDAC dual inhibitors with synergistic antitumor activity started from lead compound 33d.

Histone histone deacetylase inhibitor and application thereof

The invention provides a histone histone deacetylase inhibitor and application thereof. Specifically, the invention provides a compound of formula (I) as shown in the specification, and a pharmaceutically acceptable salt of the compound, and in the formula, the groups are defined as shown in the specification. The invention further provides a preparation method of the compound. The compound of formula (I), which is provided by the invention, can be adopted to treat a series of diseases mediated by histone histone deacetylases by inhibiting histone histone deacetylases (HDACs), particularly type-I histone histone deacetylases (subtypes such as HDAC1 and HDAC3), particularly including tumor diseases such as solid tumor and leukemia, neurodegenerative diseases, and the like.